Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Open accessThe DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Abstract
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a systematic review of clinical trials published from 1990 until 2015, assessing these therapeutic properties. Electronic searches were performed using the PubMed, LILACS, and SciELO databases. Only clinical trials published in peer-reviewed journals were included. Of these, 151 studies were identified, of which six met the established criteria. Reviewed studies suggest beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence. All drugs were well tolerated. In conclusion, ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients. These drugs may also be useful pharmacological tools to understand psychiatric disorders and to develop new therapeutic agents. However, all studies reviewed had small sample sizes, and half of them were open-label, proof-of-concept studies. Randomized, double-blind, placebo-controlled studies with more patients are needed to replicate these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“these medicines have demonstrated efficacy across a range of neuropsychiatric disorders including depression, PTSD, and addiction (156, 168–172)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [31]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Research works printed but not linked: 16
- Furst P., 1994, Alucinógenos y cultura
- Grob C., 1998, Heffter Rev Psychedelic Res, 1, 8
- Grof S., 2001, LSD psychotherapy
- Halpern J., 2008, Med Sci Monit, 14, SR15
- Harner M., 1976, Alucinógenos y chamanismo
- Hintzen A., 2010, The pharmacology of lysergic acid diethylamide: a critical review
- Hofmann A., 2005, LSD: my problem child
- House R., 1997, NIDA Res Monogr, 173, 175
- Labate B., 2009, Ayahuasca religions: a comprehensive bibliography and critical essays
- Lima L., 2006, Ärztez Naturheilverfahren, 47, 476
- Ott J., 1994, Ayahuasca analogues: pangaean entheogens
- Ott J., 2004, Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia
- Réus G., 2012, Depress Res Treat, 2012, 987397
- Schultes R., 1986, Am Indig, 46, 9
- Schultes R., 1998, Heffter Rev Psychedel Res, 1, 1
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
Cited by
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
“Given the growing evidence favoring the therapeutic value of psychedelics (dos Santos et al., 2016; Rucker et al., 2016; Carhart-Harris and Goodwin, 2017), it is timely that we better understand their therapeutic mechanisms.”
BackgroundJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Self unbound: ego dissolution in psychedelic experience
Letheby, C., & Gerrans, P. (2017) · Neuroscience of Consciousness · doi:10.1093/nc/nix016 · Cited by 293
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230
dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1511424 · Cited by 227
“Evidence from two open-label studies showed improvements in symptoms of tobacco (n = 15 [72], extracted from [55]) and alcohol (n = 10 [73], extracted from [55]) dependence with administration of two psilocybin doses.”
BackgroundInfluentialSelf-citationBreeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
“It has been suggested that psychedelics such as ayahuasca might be, within an appropriate psychotherapeutic setting, useful in the treatment of substance use disorders because it can result in positive and lasting lifestyle changes (dos Santos et al. 2016).”
BackgroundUnifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 181
Hamill, J., Hallak, J., Dursun, S. M., & Baker, G. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 178
Self-citationAlmeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177
Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., & de Wit, H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.019 · Cited by 175
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172
“Hallmarks of these disorders are repetitive and rigid patterns of negative and compulsive thoughts, together with social difficulties and impaired empathic abilities (Aldao, NolenHoeksema, and Schweizer 2010; Beck 1967; Dos Santos et al. 2016; Morrison et al. 2016; Nietlisbach and Maercker 2009; Todd et al. 2015), the…”
BackgroundEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
Self-citationPsychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 167
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134
Self-citationBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111953 · Cited by 123
“has demonstrated that the administration of 100 μg of LSD enhances emotional empathy in healthy volunteers [161] However, more research needs to be performed on the differential effects of LSD and other hallucinogenic drugs at low and high doses: while at lower doses they activate 5-HT system, likely producing therape…”
BackgroundTransient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.002 · Cited by 123
Chronic pain and psychedelics: a review and proposed mechanism of action
Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F., Halberstadt, A., & Furnish, T. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101273 · Cited by 119
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 115
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
Romeo, B., Karila, L., Martelli, C., & Benyamina, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120919957 · Cited by 113
“Psychedelic drugs showed an efficacy in some psychiatric disorders like substance use disorder (tobacco, alcohol), major depressive disorder (MDD) and obsessive-compulsive disorder (dos Santos et al., 2016).”
Backgrounddos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Self-citationPsychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110
“Specifically, psilocybin has been shown to ameliorate end of life anxiety in terminal cancer patients (Griffiths et al. 2016), 3,4-methylenedioxymethamphetamine (MDMA) has produced positive effects in patients suffering from PTSD (Dunlap, Andrews, and Olson 2018), and the DMT-containing tisane known as ayahuasca has d…”
BackgroundInfluentialClassical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
“Preclinical and human research suggest that ayahuasca, psilocybin, and LSD have antidepressive, anxiolytic, and antiaddictive properties (dos Santos et al., 2016a, 2016b; Nunes et al., 2016).”
InfluentialSelf-citationSoler, J., Elices, M., Dominguez-Clavé, E., Pascual, J. C., Feilding, A., Navarro-Gil, M., García-Campayo, J., & Riba, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00224 · Cited by 102
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. (2019) · Drug and Alcohol Review · doi:10.1111/dar.12985 · Cited by 102
The Neuropsychology of Anxiety: An enquiry into the functions of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · doi:10.1093/oso/9780198843313.001.0001 · Cited by 97
Dunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
The Ethnopharmacologic Contribution to Bioprospecting Natural Products
Buenz, E. J., Verpoorte, R., & Bauer, B. A. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052703 · Cited by 109
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 120
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 103
Acute psilocybin enhances cognitive flexibility in rats
Torrado Pacheco, A., Olson, R. J., Garza, G., & Moghaddam, B. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01545-z · Cited by 87
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Gregorio, D. D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., Rahimy, Y. E., López-Canul, M., Comai, S., & Gobbi, G. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01301-9 · Cited by 101
Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
The therapeutic potential of microdosing psychedelics in depression
Kuypers, K. P. C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950567 · Cited by 84
Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder
Agrawal, M., Richards, W., Beaussant, Y., Shnayder, S., Ameli, R., Roddy, K., Stevens, N., Richards, B., Schor, N., Honstein, H., et al. (2024) · Cancer · doi:10.1002/cncr.35010 · Cited by 88
Harmine produces antidepressant-like effects via restoration of astrocytic functions
Liu, F., Wu, J., Gong, Y. L., Wang, P., Zhu, L., Tong, L., Chen, X., Ling, Y., & Huang, C. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.012 · Cited by 82
“…of the mutual interaction between astrocytes and antidepressant targets would promote the understanding about the role of harmine and other hallucinogens, such as lysergic acid diethylamide (LSD) (Dos Santos et al., 2016) and psilocybin (Carhart-Harris et al., 2016), in depression regulation.”
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
Classics in Chemical Neuroscience: Amitriptyline
McClure, E. W., & Daniels, R. N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00467 · Cited by 78
Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass
Petranker, R., Anderson, T., & Farb, N. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.01681 · Cited by 69
Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67
Winkelman, M. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.619890 · Cited by 67
“…effects on emotions and social relations could be enhanced through ritual in ways that contributed to fitness through their renowned ability to evoke a variety of healing responses (see dos Santos et al., 2016; also see Winkelman and Roberts (2007) andWinkelman and Sessa (2019) for overview).”
Backgrounddos Santos, R. G., & Hallak, J. E. C. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1260189 · Cited by 65
Self-citationPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“In fact, psychedelics have distinguished themselves as promising medicines as they elicit therapeutic responses in multiple neuropsychiatric disorders (Dos Santos et al., 2016) and produce beneficial effects that can last for months following a single administration (Kyzar et al., 2017).”
BackgroundThe emerging role of psilocybin and MDMA in the treatment of mental illness
Gill, H., Gill, B., Chen-Li, D., El-Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y., Rosenblat, J. D., Majeed, A., et al. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826931 · Cited by 61
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016025 · Cited by 61
“supporting other work demonstrating the antidepressive/ anxiolytic effects of psychedelics.(27) 40 46 55 The potential”
ResultChemical composition of traditional and analog Ayahuasca
Kaasik, H., Souza, R. C. Z., Zandonadi, F. S., Tófoli, L. F., & Sussulini, A. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1815911 · Cited by 59
dos Santos, R. G., & Hallak, J. E. C. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.053 · Cited by 56
Self-citationA Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
Brennan, B., Jackson, M. A., MacLean, K. A., & Ponterotto, J. G. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211045265 · Cited by 66
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Lowe, H. I. C., Toyang, N. J., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. F. (2022) · Molecules · doi:10.3390/molecules27082520 · Cited by 71
“Anti-depressant and anxiolytic properties of DMT have been described in an openlabel study on psychiatric inpatients with a current depressive episode, which evaluated the effects of a single dose of ayahuasca [33,35].”
BackgroundConn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Lemus, M. B., Greaves, E., Homman‐Ludiye, J., Oldfield, B. J., & Foldi, C. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02575-9 · Cited by 68
Magaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
Sexton, J. D., Nichols, C. D., & Hendricks, P. S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00896 · Cited by 48
Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Psilocybin/Psilocin
Dahmane, E., Hutson, P. R., & Gobburu, J. V. S. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.796 · Cited by 46
Badr, A. M., Attia, H., & Al-Rasheed, N. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60026-1 · Cited by 53
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 46
Souza, R. C. Z., Zandonadi, F. S., Freitas, D. P., Tófoli, L. F. F., & Sussulini, A. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.06.014 · Cited by 41
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
“Clinical trials have also examined the anxiolytic and antidepressive effects of psychedelics among terminally ill patients, individuals with treatment-resistant depression, and those struggling with problematic substance use (dos Santos et al., 2016).”
BackgroundBehavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Savoldi, R., Polari, D., Pinheiro‐da‐Silva, J., Silva, P. F., Soares, B. L., Yonamine, M., Freire, F. A. D. M., & Luchiari, A. C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00139 · Cited by 43
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
Set, Setting, and Clinical Trials: Colonial Technologies and Psychedelics
Dumit, J., & Sanabria, E. (2022) · Springer eBooks · doi:10.1007/978-981-16-7084-8_15 · Cited by 50
Andersson, M., & Kjellgren, A. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0333-3 · Cited by 39
Engineering Safer Psychedelics for Treating Addiction
Peters, J., & Olson, D. E. (2021) · Neuroscience Insights · doi:10.1177/26331055211033847 · Cited by 45
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Dudysová, D., Janků, K., Šmotek, M., Saifutdinová, E., Kopřivová, J., Bušková, J., Mander, B. A., Brunovský, M., Zach, P., Korčák, J., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602590 · Cited by 42
Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review
Simão, A. Y., Gonçalves, J., Duarte, A. P., Barroso, M., Cristóvão, A. C., & Gallardo, E. (2019) · Medicines · doi:10.3390/medicines6040106 · Cited by 51
“Agonists of these receptors, such as DMT, have been demonstrated to have antidepressant and anxiolytic activity [50,51].”
BackgroundArgento, E., Braschel, M., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 37
“…to health and wellbeing associated with psychedelic drug use in both clinical and non-clinical settings (Argento et al., 2017b; CarhartHarris et al., 2016a; dos Santos et al., 2016; Griffiths et al., 2016; Hendricks et al., 2015; Krebs and Johansen, 2013; Ross et al., 2016; Sanches et al., 2016).”
The antiaddictive effects of ibogaine: A systematic literature review of human studies
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2016.001 · Cited by 36
Self-citationChadeayne, A. R., Pham, D. N. K., Reid, B. G., Golen, J. A., & Manke, D. R. (2020) · ACS Omega · doi:10.1021/acsomega.0c02208 · Cited by 43
Rossi, G. N., Guerra, L. T. L., Baker, G. B., Dursun, S. M., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Biomolecules · doi:10.3390/biom12111618 · Cited by 40
Self-citationMarcus, O. (2022) · Interdisciplinary Science Reviews · doi:10.1080/03080188.2022.2075201 · Cited by 38
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
O’Shaughnessy, D. M., Berlowitz, I., Rodd, R., Sarnyai, Z., & Quirk, F. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320986634 · Cited by 33
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058933 · Cited by 38
“…and substance use disorders (Bogenschutz and Johnson, 2016; Johnson et al., 2014; Pisano et al., 2017), anxiety disorders (Danforth et al., 2018; Dos Santos et al., 2016; Gasser et al., 2014; Griffiths et al., 2016), and trauma-related disorders (Mithoefer et al., 2016, 2011, 2013, 2019;…”
BackgroundSharma, R., Batchelor, R., & Sin, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2190319 · Cited by 39
“LSD is a semisynthetic serotonergic substance whose defining psychoactive properties (i.e. antidepressant and anxiolytic effects) are thought to be mediated primarily through serotonin type 2A receptor agonism (Dos Santos et al. 2016).”
BackgroundEfficacité des psychédéliques en psychiatrie, une revue systématique
Berkovitch, L., Roméo, B., Karila, L., Gaillard, R., & Benyamina, A. (2021) · L Encéphale · doi:10.1016/j.encep.2020.12.002 · Cited by 36
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 37
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M., van Oorsouw, K. I. M., Delgado, A. R. O., & Ramaekers, J. G. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.857372 · Cited by 38
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 54
Džodić, J., Milenković, D., Marković, M., Marković, Z., & Dimić, D. (2023) · Applied Sciences · doi:10.3390/app13052984 · Cited by 29
Acute Intoxication following Dimethyltryptamine Ingestion
Bilhimer, M. H., Schult, R. F., Higgs, K. V., Wiegand, T. J., Gorodetsky, R. M., & Acquisto, N. M. (2018) · Case Reports in Emergency Medicine · doi:10.1155/2018/3452691 · Cited by 30
“However, despite such reports, there is also evidence suggesting ayahuasca may have clinical benefit in treating anxiety, treatment resistant-depression, and drug and alcohol dependence [17, 18].”
Background
Metadata
- Authors
- dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C.
- Affiliations
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil National Institute for Translational Medicine (INCT-TM), CNPq, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-18
- Volume
- 6
- Issue
- 3
- Pages
- 193-213
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910400
- OpenAlex
- W2325558246
- Cited by
- 306
- References
- 196
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 50 · 2023: 28 · 2022: 32 · 2021: 44 · 2020: 35 · 2019: 27 · 2018: 29 · 2017: 20 · 2016: 5
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, psilocybin, lysergic acid diethylamide, antidepressant effects, anxiolytic effects, treatment-resistant depression, anxiety disorders, drug addiction, tobacco dependence, alcoholism, psychedelics, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.